| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
J Thorac Cardiovasc Surg 2002;123:550-556
© 2002 The American Association for Thoracic Surgery
Cardiopulmonary Support and Physiology (CSP) |
From the Divisions of Cardiac Surgerya and Cardiologyb, Cardio-Thoracic Department, University of Pisa Medical School, Pisa, Italy.
Received for publication June 21, 2001; revisions requested Aug 25, 2001; revisions received Sept 4, 2001; accepted for publication Sept 10, 2001. Address for reprints: U. Bortolotti, MD, U.O. Cardiochirurgia, Ospedale Cisanello, Via Paradisa 2, 56124 Pisa, Italy (E-mail: u.bortolotti{at}cardchir.med.unipi.it).
Objective: A prospective clinical study was designed to assess the frequency and severity of intravascular hemolysis in patients with new-generation, normally functioning prosthetic heart valves.
Methods: Hemolysis was evaluated in 172 patients with a mechanical prosthesis (53 CarboMedics and 119 Sorin Bicarbon) and in 106 patients with a bioprosthesis (15 St Jude Medical Toronto, 19 Baxter Perimount, and 72 Medtronic Mosaic) in the aortic position, mitral position, or both. Aortic valve replacement was performed in 206 patients, mitral valve replacement in 59 patients, and double valve replacement in 13 patients. The presence of hemolysis was assessed on the basis of the level of serum lactic dehydrogenase and serum haptoglobin and the presence and amount of reticulocytes and schistocytes in the peripheral blood. Severity of intravascular hemolysis was estimated on the basis of serum lactic dehydrogenase. Clinical, echocardiographic, and hematologic evaluations were performed 1, 6, and 12 months after discharge.
Results: None of the 278 patients experienced decompensated anemia, whereas at 12 months, mild subclinical hemolysis was identified in 49 patients, 44 (26%) with a mechanical prosthesis and 5 (5%) with a bioprosthesis (P < .001). At multivariate analysis, independent predictors of the presence of subclinical hemolysis were mitral valve replacement (P < .001), use of a mechanical prosthesis (P = .002), and double valve replacement (P = .02). Frequency of hemolysis in patients with stented aortic bioprostheses was 3%, whereas it was absent in those with stentless valves. Among mechanical valve recipients, double versus single valve replacement (P = .04) and mitral versus aortic valve replacement (P = .05) were correlated with the presence of hemolysis; double valve recipients also showed a more severe degree of hemolysis (P = .03). In patients with a Sorin Bicarbon prosthesis, hemolysis was less frequent (22% vs 34%, P = .09) and severe (P < .001) than in those with a CarboMedics prosthesis.
Conclusions: In normally functioning prosthetic heart valves, subclinical hemolysis is a frequent finding. A low incidence of hemolysis is found in stented biologic prostheses, and it is absent in stentless aortic valves. Modifications of valve design may contribute to minimize the occurrence of hemolysis in mechanical prostheses.
This article has been cited by other articles:
|
|
 |
|
  G. M. Palatianos, A. M. Laczkovics, P. Simon, J. L. Pomar, D. E. Birnbaum, H. H. Greve, and A. Haverich Multicentered European Study on Safety and Effectiveness of the On-X Prosthetic Heart Valve: Intermediate Follow-Up Ann. Thorac. Surg., January 1, 2007; 83(1): 40 - 46. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. R. Buchanan and M. J. Kahn Hemolytic anemias ASH Self-Assessment Program, January 1, 2007; 2007(1): 102 - 142. [Full Text] [PDF]
|
|
|
|
|
|
M. Josa, M. Castella, C. Pare, J. L. Bedini, R. Cartana, C. A. Mestres, J. L. Pomar, and J. Mulet Hemolysis in Mechanical Bileaflet Prostheses: Experience With the Bicarbon Valve Ann. Thorac. Surg., April 1, 2006; 81(4): 1291 - 1296. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
